PURA COVID-19 Update #5 – Covid-19 CBD Market Impact Study – Evolution and 32% Sustained Annual Growth
 


 

Dallas, TX -- April 27, 2020 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today released its fifth weekly Coronavirus Market update.  With a market restart anticipated to begin ramping up in the weeks to come, PURA is making a careful study of the anticipated Covid-19 impact on the overall CBD market.  In short, the CBD market is anticipated to sustain 31.9% annual growth through 2027 with CBD product innovation and market channel evolution resulting from Covid-19 policy influences.  Among other resources, PURA is looking at the Data Bridge Market Research announced just last week that includes a Covid-19 CBD Market Analysis. 

PURA management anticipates the Coronavirus Pandemic to create both issues and opportunities during and after the crisis.  Management plans to carefully continue to evaluate potential issues and opportunities and maintain publishing weekly updates in order to provide stakeholders with the most current information and insight into management thinking throughout this highly fluid business environment.

So far, the impact to PURA has been minimal.  PURA was fortunate enough to execute a production run of its primary revenue generator, EVERx CBD Sports Water, just prior to the shutdown and now, with light at the end of the tunnel, it appears PURA will make it through to the reopening of the economy with its current inventory.

PURA continues with its acquisition campaign launched earlier this year.  PURA recently announced initiating three new due diligence efforts resulting from new opportunities that management attributes to the impact of the Coronavirus economic situation on businesses in general.  Puration’s CEO, Brian Shibley, plans to publish an update later this week on PURA’s ongoing acquisition campaign highlighting the company’s patented CBD extraction process patent.

PURA management continues to advance a prompt publishing of the annual financial report for 2019.  The company filed an extension in conjunction with the current Covid-19 extension parameters and plans to publish its financial report before the deadline for the current extension parameters.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,

info@aciconglomerated.com
(800) 861-1350

 

Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Puration (CE) Charts.
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Puration (CE) Charts.